BCI
TBPH

Brinker Capital Investments’s Theravance Biopharma TBPH Stock Holding History

Brinker Capital Investments’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$179K Buy
10,544
+301
+3% +$4.98K ﹤0.01% 1822
2026
Q1 		$166K Buy
+10,243
New +$181K ﹤0.01% 1886

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Brinker Capital Investments's TBPH Position: Q2 2026 in Review

Brinker Capital Investments increased its Theravance Biopharma (TBPH) stake by 2.9% in Q2 2026, buying an estimated $4.98K and bringing the position to 10,544 shares worth $179K. The position accounts for ﹤0.01% of the portfolio, ranked #1822.

Brinker Capital Investments first reported a position in TBPH in Q1 2026 and has held it in 2 quarters since. 180 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Brinker Capital Investments held 10,544 shares of Theravance Biopharma worth $179K as of Q2 2026.
  • Brinker Capital Investments bought 301 Theravance Biopharma shares in Q2 2026, an estimated $4.98K.
  • Theravance Biopharma made up ﹤0.01% of Brinker Capital Investments's portfolio in Q2 2026, its #1822 holding.
  • Brinker Capital Investments first reported a position in Theravance Biopharma in Q1 2026 and has held it in 2 quarters since.
  • 180 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Brinker Capital Investments's 13F filing for Q2 2026, filed 14 Aug 2026.